<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04668612</url>
  </required_header>
  <id_info>
    <org_study_id>1.1</org_study_id>
    <nct_id>NCT04668612</nct_id>
  </id_info>
  <brief_title>Dual-wave Boluses in Children With Type 1 Diabetes Insulin Boluses in Children With Type 1 Diabetes</brief_title>
  <official_title>Lowering Postprandial Hyperglycemia With Dual-wave Insulin Boluses in Children With Type 1 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tartu University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Estonian Research Council</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Tartu University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To analyze with the aid of CGM the blood sugar profiles of children receiving dual-wave&#xD;
      versus standard bolus for dinner.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary objective To analyze with the aid of CGM the blood sugar profiles of children&#xD;
      receiving dual-wave versus standard bolus for dinner.&#xD;
&#xD;
      Primary endpoint To compare time in range (TIR) during 2 weeks receiving dual-wave bolus&#xD;
      versus standard bolus for dinner.&#xD;
&#xD;
      Trial design This is a 28-day long prospective randomized open-label single-center crossover&#xD;
      clinical study with a 14-day long run-in phase.&#xD;
&#xD;
      Trial population A total of 30 subjects with type 1 diabetes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 4, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 20, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Randomized open-label single-center crossover clinical study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time in range (TIR) during 2 weeks receiving dual-wave bolus versus standard bolus for dinner.</measure>
    <time_frame>14 days</time_frame>
    <description>To compare time in range duration during 2 weeks receiving dual-wave bolus versus standard bolus for dinner. Proportion of time in range (3.9-10 mmol/L) will be measured.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time below range (TBR) during 2 weeks receiving dual-wave bolus versus standard bolus for dinner.</measure>
    <time_frame>14 days</time_frame>
    <description>Time below range (TBR) during 2 weeks receiving dual-wave bolus versus standard bolus for dinner. Proportion of time below range (&lt;3,9 mmol/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time above range (TAR) during 2 weeks receiving dual-wave bolus versus standard bolus</measure>
    <time_frame>14 days</time_frame>
    <description>Time above range (TAR) during 2 weeks receiving dual-wave bolus versus standard bolus for dinner. Proportion of time below range (&gt;10.0 mmol/L)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Type 1 Diabetes</condition>
  <arm_group>
    <arm_group_label>Standard-bolus</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard boluses for all meal</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dual-bolus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dual-bolus (50/50% with second part over 2 hours) for all meals after 6:00 p.m</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Dual-bolus</intervention_name>
    <description>Dual-bolus (50/50% with second part over 2 hours) for all meals after 6:00 p.m.</description>
    <arm_group_label>Dual-bolus</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Standard bolus</intervention_name>
    <description>Standard boluses for all meals</description>
    <arm_group_label>Standard-bolus</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Children aged 7-18 years treated at the Children's Clinic of Tartu University Hospital&#xD;
             for type1 diabetes.&#xD;
&#xD;
          2. Insulin pump and CGM initiated at least 3 months prior to the recruitment.&#xD;
&#xD;
          3. Estimated HbA1c based on the 14-days CGM report above 8.5%.&#xD;
&#xD;
          4. Daily insulin dose of more than 0.5 international units per kilogram.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects with known diabetes complications.&#xD;
&#xD;
          2. Elevated tissue transglutaminase IgA antibodies in the last two years.&#xD;
&#xD;
          3. Children who developed an acute viral infections during the week preceding the&#xD;
             recruitment.&#xD;
&#xD;
        Exclusion criteria after the Run-in period&#xD;
&#xD;
          1. Basal insulin proportion &gt; 55% of daily insulin dose.&#xD;
&#xD;
          2. Children with any symptoms of an infectious disease or acutely sick during the last&#xD;
             two weeks.&#xD;
&#xD;
          3. Estimated HbA1c &gt; 8.5% based on the 14-days CGM report.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>7 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Tartu University Hospital</name>
      <address>
        <city>Tartu</city>
        <zip>51014</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Estonia</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>November 30, 2020</study_first_submitted>
  <study_first_submitted_qc>December 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 16, 2020</study_first_posted>
  <last_update_submitted>March 30, 2021</last_update_submitted>
  <last_update_submitted_qc>March 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tartu University Hospital</investigator_affiliation>
    <investigator_full_name>Aleksandr Peet</investigator_full_name>
    <investigator_title>pediatric endocrinologist, MD, PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

